DINUCLEAR PLATINUM(II) COMPLEX WITH OXADIAZOL ADAMANTANE

The discovery of cisplatin, in the late’s 1960’s, enhanced the metallic compounds studies for cancer treatment. Despite its success in the clinic and its broad utilization in the treatment of several types of cancer, it may cause cell resistance and severe side effects. These factors motivated studies of a great number of platinum derivative compounds, such as bi- or tri-homonuclear complexes, that show different cellular uptake mechanisms and lower cell resistance1. With the aim to obtain a more effective and less toxic compound, a new dinuclear platinum complex was synthesized with heterocyclic 1,3,4-oxadiazolines ligands (ligand A) that could confer lipophilicity and potential anticancer activity. The complex was synthesized as shown above in 71% yield and was characterized by elemental analysis, X-ray crystallography, infrared and 1H, 13C and 195Pt NMR. Data suggests that a Pt dinuclear complex was obtained with four bridging ligands, each coordinated by the N and S atoms, as confirmed by single crystal X-ray analysis. 195Pt NMR spectra showed a single signal at -3032,92 ppm, due to high symmetry2. The absence of ʋNH band in infrared spectra indicates that ligand A assumes its tautomeric form in complex 1. Activity against tumor cells are ongoing.